| Ginger Jo James, LCP CADC-I | |
|
201 Main St, Atchison, KS 66002-2838 | |
| (913) 367-1593 | |
| Not Available |
| Full Name | Ginger Jo James |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 201 Main St, Atchison, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407921992 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | CADCI (Kansas) | Secondary |
| 101YM0800X | Counselor - Mental Health | LCP 908 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ginger Jo James, LCP CADC-I 201 Main St, Atchison, KS 66002-2838 Ph: (913) 367-1593 | Ginger Jo James, LCP CADC-I 201 Main St, Atchison, KS 66002-2838 Ph: (913) 367-1593 |
News Archive
Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.
In part four of a blog series that addresses how to leverage a hospital pharmacy as a strategic asset, Mary Baxter, MBA, RPh., vice president and national practice leader for Cardinal Health's Innovation Delivery Solutions business, discusses how expanding patient access to quality pharmacy care can benefit both hospitals and patients.
Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.
Roche announced today the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research.
Fluoxetine was the first drug approved by the FDA for major depressive disorder (MDD) in children and adolescents, and to this date, it remains one of only two selective serotonin reuptake inhibitors (SSRIs) registered for treatment of MDD in children and adolescents, despite reports that indicate this class of drugs is associated with side effects, such as agitation, hostility and aggression.
› Verified 5 days ago
Dillan Soph, LCAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1816 N 2nd St, Atchison, KS 66002 Phone: 913-367-1618 | |
Jennifer D Cavin, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 104 N 6th St, Suite 7, Atchison, KS 66002 Phone: 913-367-0105 Fax: 913-367-3959 | |
Jack Selberg, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1816 N 2nd St, Atchison, KS 66002 Phone: 913-367-1618 Fax: 913-367-6224 | |
Lauren Mackenzie Graham, LMSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 1412 N 2nd St, Atchison, KS 66002 Phone: 913-367-4879 | |
Mr. Elmer Fangman, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1225 N 2nd St, Atchison, KS 66002 Phone: 913-367-0105 Fax: 913-367-0105 | |
Patricia Wick, Counselor Medicare: Not Enrolled in Medicare Practice Location: 201 Main St, Atchison, KS 66002 Phone: 913-367-1593 |